OpenAI's $34B Spending Pushes AI Market Leadership Ahead of IPO 
North Korea Reports Industrial Output at 105% of Target Following Party Congress 
Dollar Slips as U.S.-Iran Peace Deal Optimism Boosts Risk Appetite Ahead of Fed Decision 
Oil Prices Recover Slightly as U.S. Crude Inventories Fall, But Iran Deal Caps Gains 
Dollar Slips as U.S.-Iran Peace Deal Boosts Risk Appetite and Pressures Safe-Haven Demand 
SpaceX Stock Gets $175 Target as Analysts See Massive Growth Ahead 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
U.S. Gasoline Prices Fall Below $4 as U.S.-Iran Deal Eases Oil Market Concerns 
BOJ Raises Interest Rates to 31-Year High, Signals Strong Focus on Inflation Risks 
UK Banks Report Surge in APP Fraud Losses as Pressure Mounts on Meta and Tech Platforms 
Trump Administration Closes Delta Air Lines Investigation Over 2024 CrowdStrike Outage 
Roku Explores Sale Options as Interest Grows in Streaming and Ad Business 
China Industrial Output Beats Forecasts as Domestic Demand Weakens 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
GM Explores Defense Manufacturing Partnership With Lockheed Martin 
Anthropic Officials Meet White House Over AI Model Outage 
Celltrion Healthcare will bring its parent company’s adalimumab biosimilar called Yuflyma to Europe next month. The company is in charge of Celltrion’s businesses overseas, and it will be launching the said biosimilar drug and start its sale in European countries.
The launch of Yuflyma
As per The Korea Herald, Celltrion will introduce Yuflyma in six European regions at first. A company official reportedly said that they will attempt to release the product in Spain this coming June, but this date could still change.
Celltrion’s Yuflyma is said to be the world’s first biosimilar of Humira, the original drug containing adalimumab and made by AbbVie pharmaceutical company, a spin-off of Abbott Laboratories.
In the third quarter of this year, Celltrion Healthcare is aiming to launch the drug in seven additional European countries and will include France and Germany. In the last quarter, it will roll out in three more regions, including Italy.
Approval of Celltrion’s Biosimilar
The European Commission handed down the authorization for Yuflyma in February. The agency approved it for use in Europe for the treatment of patients suffering from 13 chronic inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, pediatric uveitis, juvenile idiopathic arthritis, and ulcerative colitis.
Celltrion Healthcare shared that the company was given the EU marketing authorization for the high-concentration, citrate-free adalimumab biosimilar. It will be sold under the Yuflyma brand name, which was called the CT-P17 when it was still being developed.
The citrate-free and high concentration formulation, which is 100mg/mL, was applied to lessen the dosage of the existing drug by half. In comparison, most of the Humira biosimilars have low concentrations of the drug.
The Center for Biosimilars stated that the approval is notable because even if the European market has many adalimumab biosimilars already, this one coming from Celltrion has no citrate, a substance that is said to make the drug administration painful for patients. Apparently, it was removed to avoid pain.
Celltrion’s entrance into the adalimumab manufacturing also makes it the first to compete in this new market but with a lower-cost biosimilar. Meanwhile, the approval from the EU commission was followed by positive opinions from the European Medicines Agency (EMA) and the Committee for Medicinal Products for Human Use (CHMP).
